Drug Resistance, Neoplasm
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in the URMC Research Network by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publication.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
-
Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011 May 1; 128(9):2075-84.
-
Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Janarthanan B, Cheney RT. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod Pathol. 2011 Aug; 24(8):1055-9.
-
Mohile NA, Zoccoli CM, Glantz M. Is brain the new bone marrow? Stem cells, cancer, and cognition: a working hypothesis. Neurology. 2011 Mar 29; 76(13):1118-20.
-
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011 Feb 10; 29(5):591-9.
-
Benoit DS, Henry SM, Shubin AD, Hoffman AS, Stayton PS. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm. 2010 Apr 5; 7(2):442-55.
-
Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 2010 Sep; 17(9):1381-91.
-
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010 Jun 3; 115(22):4478-87.
-
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28.
-
Bassili M, Birman E, Schor NF, Saragovi HU. Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemother Pharmacol. 2010 May; 65(6):1047-56.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
